Neurol. praxi. 2022;23(4):324-329 | DOI: 10.36290/neu.2022.035

Migraine treatment in patients with poor compliance

MUDr. Jana Múdra
Neurologická ambulancia, Košice

Compliance is a key factor in the treatment of many chronic diseases. In the dictionary it means agreement, willingness, consistency and cooperation. Adherence has similar meaning. Poor treatment adherence is associated with poor results and decreases with the complexity of the treatment. Inadequate usage of headache treatment, including overuse of medication as well as underuse, can exacerbate headaches and is a risk factor for the development of chronic migraine. Despite the importance of treatment adherence, there are very few studies that have examined adherence of patients suffering from migraine. Available studies indicate that acute and prophylactic medication adherence in migraine treatment is low. Currently, new options are available for migraine treatment that also improve the compliance.

Keywords: migraine, compliance, adherence, acute and prophylactic treatment, monoclonal antibodies against CGRP.

Received: April 24, 2022; Revised: May 27, 2022; Accepted: June 7, 2022; Prepublished online: June 7, 2022; Published: August 30, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Múdra J. Migraine treatment in patients with poor compliance. Neurol. praxi. 2022;23(4):324-329. doi: 10.36290/neu.2022.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ashina M, Goadsby PJ, Reuter U, et al. Long­‑term safety and tolerability of erenumab: Three­‑plus year results from a five­‑year open­‑label extension study in episodic migraine. Cephalalgia. 2019;39:1455-1464. doi: 10.1177/0333102419854082. Go to original source... Go to PubMed...
    2. Ashina M, Goadsby PJ, Reuter U, et al. Long­‑term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open­‑label treatment phase of a randomized clinical trial. Eur. J. Neurol. 2021;28:1716-1725. doi: 10.1111/ene.14715. Go to original source... Go to PubMed...
    3. Ashina M, Kudrow D, Reuter U, et al. Long­‑term tolerability and nonvascular safety of erenumab, a novel calcitonin gene­‑related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo­‑controlled trials with long­‑term extensions. Cephalalgia. 2019;39:1798-1808. doi: 10.1177/0333102419888222 Go to original source... Go to PubMed...
    4. Aurora SK, Dodick DW, Turkel CC, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double­‑blind, randomized, placebo­‑controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793-803. Go to original source... Go to PubMed...
    5. Bártková A. Akutní a profylaktická terapie migrény. Prakt. lékáren. 2019;15(4):208-212.
    6. Bigal ME, Serrano D, Buse D. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population­‑based study. Headache. 2008;48(8):1157-68. Go to original source... Go to PubMed...
    7. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract. 2007;61:1922-30. Go to original source... Go to PubMed...
    8. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta­‑analysis. Med Care. 2002;40(9):794-811. Go to original source... Go to PubMed...
    9. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200-09. Go to original source... Go to PubMed...
    10. Diener HC, Dodick DW, Aurora SK, et al. PREEMPT 2 chronic migraine study group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double­‑blind, randomized, placebo­‑controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-814. Go to original source... Go to PubMed...
    11. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double­‑blind, placebo­‑controlled, phase 3 b trial. Lancet. 2019;394:1030-1040. doi: 10.1016/S0140-6736(19)31946-4. Go to original source... Go to PubMed...
    12. Goadsby PJ, Reuter U, Hallström Y, et al. One­‑year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. 2020;95:e469-e479. doi: 10.1212/WNL.0000000000010019. Go to original source... Go to PubMed...
    13. Goadsby PJ, Dodick DW, Leone M, et al. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N. Engl. J. Med. 2019;381:132-141. doi: 10.1056/NEJMoa1813440. Go to original source... Go to PubMed...
    14. Goadsby PJ, Silberstein SD, Yeung PP, et al. Long­‑term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 2020;95:2487-2499. doi: 10.1212/WNL. Go to original source...
    15. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765. Go to original source... Go to PubMed...
    16. Grundmann M. Compliance. Klin farmakol farmac. 1999;13:3-5.
    17. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011. Go to original source... Go to PubMed...
    18. Hazard E, Munakata J, Bigal ME, et al. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health. 2009;12(1):55-64. Go to original source... Go to PubMed...
    19. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22-33. Go to original source... Go to PubMed...
    20. Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine­‑preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478-488. Go to original source... Go to PubMed...
    21. Leonadri M, Steiner TJ, Sacher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO's classification of Functioning, disability and Health (ICF). J Headache Pain. 2005;6(6):429-440. Go to original source... Go to PubMed...
    22. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9. Go to original source... Go to PubMed...
    23. Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new­‑onset chronic migraine. Neurology. 2015;84(7):688-95. Go to original source... Go to PubMed...
    24. Luykx J, Mason M, Ferrari MD, et al. Are migraineurs at increased risk of adverse drug responses? A meta­‑analytic comparison of topiramate­‑related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009;85:283-288. Go to original source... Go to PubMed...
    25. Nicholson RA, Chibnall JT, Ng­‑Mak D, et al. Why wait? Reasons that patients delay taking a triptan during individual migraine attacks. Headache. 2011;51(S1):S6-7.
    26. Nicholson RA, Smith TR. Likelihood of patients adhering to acute medication during migraine attacks. Submitted for presentation at the annual scientific meeting of the American Headache Society, Washington, DC.
    27. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97. Go to original source... Go to PubMed...
    28. Reed ML, Fanning KM, Serrano D, et al. Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results. Headache. 2015;55(1):76-87. Go to original source... Go to PubMed...
    29. Rains JC, Lipchik GL, Penzien DB. Behavioral facilitation of medical treatment for headache-part I: review of headache treatment compliance. Headache. 2006;46(9):1387-94. Go to original source... Go to PubMed...
    30. Ramsey RR, Ryan JL, Hershey AD, et al. Treatment adherence in patients with headache: a systematic review. Headache J Head Face Pain. 2014;54(5):795- 816. Go to original source... Go to PubMed...
    31. Silberstein SD, Holland S, Freitag F, et al. Quality standards Subcommittee of the American Academy of neurology and the American headache society. Evidence­‑based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of neurology and the American headache society. Neurology. 2012;78:1337-134. Go to original source... Go to PubMed...
    32. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490-495. Go to original source... Go to PubMed...
    33. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442-1454. doi: 10.1177/0333102418779543. Go to original source... Go to PubMed...
    34. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N. Engl. J. Med. 2017;377:2113-2122. doi: 10.1056/NEJMoa1709038. Go to original source... Go to PubMed...
    35. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75:1080-1088. doi: 10.1001/jamaneurol.2018.1212. Go to original source... Go to PubMed...
    36. Stauffer VL, Wang S, Voulgaropoulos M, et al. Effect of Galcanezumab Following Treatment Cessation in Patients with Migraine: Results from 2 Randomized Phase 3 Trials. Headache. 2019;59:834-847. doi: 10.1111/head.13508. Go to original source... Go to PubMed...
    37. Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50 s: will health politicians now take notice? J Headache Pain. 2018;19(1):17. Go to original source... Go to PubMed...
    38. Tepper SJ, Ashina M, Reuter U, et al. Long­‑term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open­‑label extension study. Cephalalgia Int. J. Headache. 2020;40:543-553. doi: 10.1177/0333102420912726. Go to original source... Go to PubMed...
    39. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-40. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.